Literature DB >> 28434114

A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.

Stéphane Goutagny1, Marco Giovannini2, Michel Kalamarides3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28434114     DOI： 10.1007/s11060-017-2447-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  4 in total

1.  Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Authors:  Stéphane Goutagny; Eric Raymond; Marina Esposito-Farese; Stéphanie Trunet; Christian Mawrin; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Marco Giovannini; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

2.  mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Authors:  Marco Giovannini; Nicolas-Xavier Bonne; Jeremie Vitte; Fabrice Chareyre; Karo Tanaka; Rocky Adams; Laurel M Fisher; Laurence Valeyrie-Allanore; Pierre Wolkenstein; Stephane Goutagny; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

3.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

4.  Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Authors:  Eva Dombi; Simone L Ardern-Holmes; Dusica Babovic-Vuksanovic; Fred G Barker; Steve Connor; D Gareth Evans; Michael J Fisher; Stephane Goutagny; Gordon J Harris; Diego Jaramillo; Matthias A Karajannis; Bruce R Korf; Victor Mautner; Scott R Plotkin; Tina Y Poussaint; Kent Robertson; Chie-Schin Shih; Brigitte C Widemann
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910
  4 in total
  5 in total

1.  EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Authors:  Steven P Angus; Janet L Oblinger; Timothy J Stuhlmiller; Patrick A DeSouza; Roberta L Beauchamp; Luke Witt; Xin Chen; Justin T Jordan; Thomas S K Gilbert; Anat Stemmer-Rachamimov; James F Gusella; Scott R Plotkin; Stephen J Haggarty; Long-Sheng Chang; Gary L Johnson; Vijaya Ramesh
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

2.  2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Michael J Fisher; Allan J Belzberg; Peter de Blank; Thomas De Raedt; Florent Elefteriou; Rosalie E Ferner; Marco Giovannini; Gordon J Harris; Michel Kalamarides; Matthias A Karajannis; AeRang Kim; Conxi Lázaro; Lu Q Le; Wei Li; Robert Listernick; Staci Martin; Helen Morrison; Eric Pasmant; Nancy Ratner; Elisabeth Schorry; Nicole J Ullrich; David Viskochil; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette Bakker; Eduard Serra
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.578

Review 3.  An update on the CNS manifestations of neurofibromatosis type 2.

Authors:  Shannon Coy; Rumana Rashid; Anat Stemmer-Rachamimov; Sandro Santagata
Journal:  Acta Neuropathol       Date:  2019-06-04       Impact factor: 17.088

4.  Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Authors:  Robert Allaway; Steve P Angus; Roberta L Beauchamp; Jaishri O Blakeley; Marga Bott; Sarah S Burns; Annemarie Carlstedt; Long-Sheng Chang; Xin Chen; D Wade Clapp; Patrick A Desouza; Serkan Erdin; Cristina Fernandez-Valle; Justin Guinney; James F Gusella; Stephen J Haggarty; Gary L Johnson; Salvatore La Rosa; Helen Morrison; Alejandra M Petrilli; Scott R Plotkin; Abhishek Pratap; Vijaya Ramesh; Noah Sciaky; Anat Stemmer-Rachamimov; Tim J Stuhlmiller; Michael E Talkowski; D Bradley Welling; Charles W Yates; Jon S Zawistowski; Wen-Ning Zhao
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

5.  mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.

Authors:  Roberta L Beauchamp; Serkan Erdin; Luke Witt; Justin T Jordan; Scott R Plotkin; James F Gusella; Vijaya Ramesh
Journal:  J Biol Chem       Date:  2020-12-09       Impact factor: 5.486
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.